Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.
There is a perfusion deficit in Alzheimer's disease (AD), commencing in the precuneus and spreading to other parts of the cerebral cortex. The deficit anticipates the development of dementia, contributes to brain damage, and is caused by both functional and structural abnormalities of the cerebral vasculature. Most of the abnormalities are probably secondary to the accumulation of Aβ but the consequent hypoperfusion may, in turn, increase Aβ production. In the early stages of disease, abnormalities that cause vasoconstriction predominate. These include cholinergic vascular denervation, inhibition of endothelial nitric oxide synthase, increased production of endothelin-1 production and possibly also of angiotensin II. Patients with AD also have an increased prevalence of structural disease of cerebral microvessels, particularly CAA and capillary damage, and particularly in the later stages of disease these are likely to make an important contribution to the cerebral hypoperfusion. The metabolic abnormalities that cause early vascular dysfunction offer several targets for therapeutic intervention. However, for intervention to be effective it probably needs to be early. Prolonged cerebral hypoperfusion may induce compensatory circulatory changes that are themselves damaging, including hypertension and small vessel disease. This has implications for the use of antihypertensive drugs once there is accumulation of Aβ within the brain.
Dementia Research Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, United Kingom.
Seth
S
Love
Dementia Research Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, United Kingom.
J Scott
JS
Miners
D000544:Alzheimer Disease / Q000150:complications*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D002540:Cerebral Cortex / Q000098:blood supply*; D004734:Energy Metabolism / Q000502:physiology*; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications*; D008659:Metabolic Diseases / Q000150:complications*
D016229:Amyloid beta-Peptides
Alzheimer's disease; amyloid-β peptide; capillary damage; cerebral amyloid angiopathy; cholinergic innervation; endothelial nitric oxide synthase; endothelin-1; hypoperfusion; ischemia; renin-angiotensin system; vascular dysfunction